Kimberly Gentile - Net Worth and Insider Trading

Kimberly Gentile Net Worth

The estimated net worth of Kimberly Gentile is at least $51,237 dollars as of 2023-03-24. Kimberly Gentile is the SVP, Clinical Operations of Biohaven Pharmaceutical Holding Co Ltd and owns about 3,639 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) stock worth over $51,237. Details can be seen in Kimberly Gentile's Latest Holdings Summary section.

Transaction Summary of Kimberly Gentile

To

Kimberly Gentile Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kimberly Gentile owns 2 companies in total, including Biohaven Pharmaceutical Holding Co Ltd (BHVN) , and Biohaven Ltd (BHVN) .

Click here to see the complete history of Kimberly Gentile’s form 4 insider trades.

Insider Ownership Summary of Kimberly Gentile

Ticker Comapny Transaction Date Type of Owner
BHVN Biohaven Pharmaceutical Holding Co Ltd 2017-05-03 VP of Operations
BHVN Biohaven Ltd 2022-10-03 SVP & Clinical Operations

Kimberly Gentile Latest Holdings Summary

Kimberly Gentile currently owns a total of 1 stock. Kimberly Gentile owns 3,639 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) as of October 8, 2020, with a value of $51,237.

Latest Holdings of Kimberly Gentile

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BHVN Biohaven Pharmaceutical Holding Co Ltd 2020-10-08 3,639 14.08 51,237

Holding Weightings of Kimberly Gentile


Kimberly Gentile Form 4 Trading Tracker

According to the SEC Form 4 filings, Kimberly Gentile has made a total of 6 transactions in Biohaven Pharmaceutical Holding Co Ltd (BHVN) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Biohaven Pharmaceutical Holding Co Ltd is the sale of 23,500 shares on October 8, 2020, which brought Kimberly Gentile around $2 Million.

Insider Trading History of Kimberly Gentile

Ticker
Company
Date
Buy/Sell
Insider Trading Shares
Shares Change
Price
Cost
Final Share
Current Price
Price Change Since Insider Trade (%)
Filing Date
BHVN
Biohaven Pharmaceutical Holding Co Ltd
2020-10-08
Sell
23,500.00
-86.59%
$76.34
$1,793,990.00
3,639.00
$14.08
-81.56%
-
BHVN
Biohaven Pharmaceutical Holding Co Ltd
2020-06-17
Sell
24,000.00
-86.83%
$70.20
$1,684,800.00
3,639.00
$14.08
-79.94%
-
BHVN
Biohaven Pharmaceutical Holding Co Ltd
2019-11-21
Sell
25,000.00
-100.00%
$53.03
$1,325,750.00
0
$14.08
-73.45%
-
BHVN
Biohaven Pharmaceutical Holding Co Ltd
2018-06-15
Sell
12,500.00
-100.00%
$40.02
$500,250.00
0
$14.08
-64.82%
-
BHVN
Biohaven Pharmaceutical Holding Co Ltd
2018-03-01
Sell
5,000.00
-100.00%
$32.87
$164,350.00
0
$14.08
-57.16%
-
BHVN
Biohaven Pharmaceutical Holding Co Ltd
2018-02-01
Sell
5,000.00
-100.00%
$32.78
$163,900.00
0
$14.08
-57.05%
-
BHVN
Biohaven Pharmaceutical Holding Co Ltd
2018-01-02
Sell
5,000.00
-100.00%
$27.60
$138,000.00
0
$14.08
-48.99%
-
BHVN
Biohaven Pharmaceutical Holding Co Ltd
2017-12-01
Sell
5,000.00
-100.00%
$21.99
$109,950.00
0
$14.08
-35.97%
-
BHVN
Biohaven Pharmaceutical Holding Co Ltd
2017-11-01
Sell
5,000.00
-100.00%
$29.28
$146,400.00
0
$14.08
-51.91%
-
Total 9
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kimberly Gentile Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Kimberly Gentile Ownership Network

Ownership Network List of Kimberly Gentile

No Data

Ownership Network Relation of Kimberly Gentile


Kimberly Gentile Owned Company Details

What does Biohaven Pharmaceutical Holding Co Ltd do?

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Who are the key executives at Biohaven Pharmaceutical Holding Co Ltd?

Kimberly Gentile is the VP of Operations of Biohaven Pharmaceutical Holding Co Ltd. Other key executives at Biohaven Pharmaceutical Holding Co Ltd include Officer Matthew Buten , VP & Chief Accounting Officer George C. Clark , and Chief Medical Officer Elyse Stock .

Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Trades Summary

Over the past 18 months, Kimberly Gentile made no insider transaction in Biohaven Pharmaceutical Holding Co Ltd (BHVN). Other recent insider transactions involving Biohaven Pharmaceutical Holding Co Ltd (BHVN) include a net sale of 15,490 shares made by George C. Clark , a net sale of 62,265 shares made by Declan Doogan , and a net purchase of 38,000 shares made by Gregory Bailey .

In summary, during the past 3 months, insiders sold 0 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 153,613 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) were sold and 43,000 shares were bought by its insiders, resulting in a net sale of 110,613 shares.

Biohaven Pharmaceutical Holding Co Ltd (BHVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

NYSE:BHVN Insider Transactions

20/Page
Total 0
Insider
Position
Date
Buy/Sell
Shares
Shares Owned
Trade Price($)
Trade Percentage(%)
Cost($1000)
Price change since trade(%)
Share ownership details
Filing Date
20/Page
Total 0

Kimberly Gentile Mailing Address

Above is the net worth, insider trading, and ownership report for Kimberly Gentile. You might contact Kimberly Gentile via mailing address: C/o Biohaven Pharmaceutical Holding Comp, 234 Church Street, New Haven Ct 06510.